Respiratory Conditions We Study
Clinical trials for asthma, COPD, chronic cough and bronchiectasis
Pioneering Treatment Advances Through Clinical Research
At Lung Research Florida, we conduct clinical trials for difficult-to-treat respiratory conditions. Many of the studies look at whether a treatment can provide long-term disease control, not just symptom relief.
Targeted Biologic Therapies
Investigational treatments targeting specific inflammatory pathways
Precision Medicine
Biomarker-driven treatment selection
Novel Mechanisms
Investigational compounds with new mechanisms of action
Severe Asthma Clinical Trials
Investigational biologic therapies targeting inflammatory pathways
Current Research
Studies include investigational dual-pathway biologics and inhaled small-molecule therapies for severe asthma.
Anti-TSLP Monoclonal Antibodies
Investigational treatments targeting thymic stromal lymphopoietin (TSLP), studied in patients with eosinophilic and non-eosinophilic severe asthma.
Dual-Pathway Biologic Inhibitors
Investigational compounds targeting both the IL-4/IL-13 and IL-5 pathways.
Inhaled JAK1 Selective Inhibitors
Novel small molecule therapies delivered directly to the lungs, offering targeted anti-inflammatory effects with reduced systemic exposure.
Ultra-Long-Acting Anti-IL-5 Therapy
Innovative twice-yearly biologic injections for eosinophilic asthma, dramatically improving convenience and adherence. Our site took part in the IMAGINE study of this approach; enrollment in that study has now closed.
What Makes Our Asthma Trials Unique
- Comprehensive Monitoring: Regular lung function testing, inflammatory marker assessment, and quality of life evaluations
- Personalized Approach: Treatment selection based on your specific asthma phenotype
Who May Qualify for Asthma Trials
Primary Requirements
- Diagnosed with severe asthma by a pulmonologist
- Currently on high-dose inhaled medications
- Two or more severe exacerbations in the past year
- Ages 12-80 years (varies by study)
Advanced Biomarker Criteria
- Elevated blood eosinophils (≥150-300 cells/μL)
- High fractional exhaled nitric oxide (FeNO ≥25 ppb)
- Specific IgE sensitization patterns
- Failed previous biologic therapy (for some studies)
COPD Research & Clinical Trials
Investigational anti-inflammatory approaches
Current COPD Research
Our COPD studies look at whether investigational anti-inflammatory biologics and other approaches can reduce exacerbations.
Anti-IL-33 Biologic Therapy
First-in-class treatments targeting the IL-33 inflammatory pathway, shown to reduce exacerbations and slow disease progression in moderate to severe COPD patients.
Cardiopulmonary Protection Studies
Investigating how optimized COPD treatment can reduce cardiovascular events, addressing the leading cause of death in COPD patients.
IRAK4 Inhibitor Therapy
Novel oral medications targeting innate immune pathways to reduce inflammatory responses and prevent COPD exacerbations.
Precision Phenotyping Trials
Advanced studies using biomarkers to identify COPD subtypes.
Why Participate in Our COPD Trials
- Cardiovascular Monitoring: Comprehensive heart health assessment
- Quality of Life Focus: Improving daily function and exercise capacity
- Latest Technology: Study-provided COPD monitoring devices where the protocol includes them
COPD Trial Eligibility
Clinical Requirements
- Confirmed COPD diagnosis with spirometry
- FEV1 between 30-80% predicted
- History of exacerbations requiring treatment
- Ages 40-85 years
Advanced Criteria
- Elevated inflammatory markers (CRP, fibrinogen)
- Cardiovascular risk factors
- Specific emphysema or chronic bronchitis patterns
- Previous exacerbation history
Bronchiectasis Research Trials
Advanced infection prevention and airway protection therapies
Innovative Bronchiectasis Treatments (2025)
Our bronchiectasis research focuses on preventing infections and reducing exacerbations through novel bispecific antibodies and advanced airway protection strategies that target the underlying causes of bronchiectasis progression.
Anti-Pseudomonas Bispecific Antibodies
Investigational treatments targeting Pseudomonas aeruginosa infections, studied for their effect on exacerbations.
Airway Protection Biologics
Novel therapies aimed at protecting and repairing damaged airways, potentially slowing bronchiectasis progression.
Anti-Neutrophil Elastase Therapy
Targeted treatments to reduce neutrophilic inflammation and prevent further airway damage in bronchiectasis patients.
Mucoregulator Combinations
Advanced combination therapies to improve mucus clearance and reduce bacterial colonization in bronchiectatic airways.
Advantages of Our Bronchiectasis Trials
- Infection Prevention: Reducing the need for rescue antibiotics and hospitalizations
- Exacerbation Reduction: Targeted approaches to prevent bronchiectasis flare-ups
- Quality of Life: Improving daily function and reducing symptoms
- Disease Monitoring: Advanced CT imaging and biomarker assessments
- Antibiotic Sparing: Potentially reducing antibiotic resistance risks
Bronchiectasis Trial Eligibility
Clinical Requirements
- Confirmed bronchiectasis on high-resolution CT
- History of exacerbations requiring antibiotics
- Non-cystic fibrosis bronchiectasis
- Ages 18-85 years
Microbiological Criteria
- Chronic Pseudomonas aeruginosa colonization (some studies)
- Elevated inflammatory markers
- Recurrent bacterial infections
- Specific bronchiectasis severity scores
Why Choose Lung Research Florida
Respiratory research with patient-centered care
Research Excellence
Dr. Hull's 20+ years of clinical research experience with multiple FDA-approved treatments developed through our trials
Investigational Treatments
Access to investigational treatments that are not yet available outside of studies
Study Medication
Where a study includes a study medication, it is provided at no cost. Details vary by study.
Comprehensive Care
Complete medical monitoring with advanced diagnostics and expert pulmonary care throughout your trial participation
Chronic Cough
Study Closed — Not Currently RecruitingOur research center previously conducted a clinical trial for patients with chronic, unexplained cough lasting one year or more. That study has concluded.
We hope to bring additional chronic cough research opportunities to our patients in the future. If you have been living with a persistent cough that has not responded to standard treatments, we encourage you to check back periodically for updates on new trials as they become available.
For general inquiries, call our research line: 954-520-7296 x1
Learn More About Chronic Cough ResearchReady to Explore Clinical Trial Options?
Take the first step toward finding out whether a study may be right for you. Our experienced research team will guide you through the process and help determine which trials might be right for you. Visit our Frequently Asked Questions to learn more about what to expect as a clinical trial participant.
Research Referrals: 954-520-7296 x1
General Inquiries: